Denali Therapeutics (DNLI)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	92.21 mm	92.21 mm	92.21 mm	92.21 mm	92.21 mm	92.21 mm
Cash burn (monthly)	(no burn)	4.78 mm	41.06 mm	40.84 mm	19.71 mm	30.22 mm
Cash used (since last report)	n/a	13.38 mm	114.89 mm	114.27 mm	55.16 mm	84.56 mm
Cash remaining	n/a	78.83 mm	-22.68 mm	-22.06 mm	37.05 mm	7.66 mm
Runway (months of cash)	n/a	16.5	-0.6	-0.5	1.9	0.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

DNLI institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	206	182	+13.2%
Opened positions	56	32	+75.0%
Closed positions	32	56	-42.9%
Increased positions	75	59	+27.1%
Reduced positions	49	64	-23.4%

13F shares	Current	Prev Q	Change
Total value	2.66 tn	1.97 tn	+35.1%
Total shares	153.16 mm	133.73 mm	+14.5%
Total puts	38.30 k	79.80 k	-52.0%
Total calls	127.10 k	123.00 k	+3.3%
Total put/call ratio	0.3	0.6	-53.6%

Largest owners	Shares	Value	Change
Baillie Gifford & Co	13.76 mm	$319.59 bn	-2.0%
BIIB Biogen	13.31 mm	$477.44 mm	0.0%
BLK BlackRock	13.17 mm	$305.91 bn	+8.0%
Vanguard	11.31 mm	$262.67 bn	+3.1%
ARCH Venture Fund VIII	10.67 mm	$893.61 mm	0.0%
Wellington Management	9.82 mm	$228.11 bn	+18.8%
Capital Research Global Investors	7.13 mm	$165.48 bn	+17.8%
Douglas K Bratton	6.86 mm	$0.00	0.0%
Temasek	5.71 mm	$132.50 bn	0.0%
Crestline Management	4.76 mm	$110.54 bn	-8.6%

Largest transactions	Shares	Bought/sold	Change
Baker Bros. Advisors	3.73 mm	+3.73 mm	NEW
Marshall Wace	2.42 mm	+2.42 mm	NEW
Ubs Global Asset Management Americas	2.30 mm	+2.30 mm	NEW
STT State Street	4.43 mm	-1.89 mm	-29.9%
Alliancebernstein	2.02 mm	+1.88 mm	+1366.7%
Credit Suisse	0.00	-1.57 mm	EXIT
Wellington Management	9.82 mm	+1.55 mm	+18.8%
Casdin Capital	1.30 mm	+1.30 mm	NEW
Citadel Advisors	1.22 mm	+1.22 mm	NEW
Gilder Gagnon Howe & Co	0.00	-1.17 mm	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

DNLI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
25 Nov 24	Ho Carole	Common Stock	Option exercise	Acquire M	No	No	0.68	17,845	12.13 k	136,655
25 Nov 24	Ho Carole	Stock Option Common Stock	Option exercise	Dispose M	No	No	0.68	17,845	12.13 k	107,155
22 Nov 24	Schuth Alexander O.	Common Stock	Option exercise	Acquire M	No	No	0.68	20,516	13.95 k	198,582
22 Nov 24	Schuth Alexander O.	Stock Option Common Stock	Option exercise	Dispose M	No	No	0.68	20,516	13.95 k	124,562
11 Nov 24	Schenkein David P	Common Stock	Sell	Dispose S	No	Yes	32.87	32,312	1.06 mm	9,220
11 Nov 24	Schenkein David P	Common Stock	Sell	Dispose S	No	Yes	32.09	27,129	870.57 k	41,532
11 Nov 24	Schenkein David P	Common Stock	Option exercise	Acquire M	No	No	18	47,165	848.97 k	68,661
11 Nov 24	Schenkein David P	Stock Option Common Stock	Option exercise	Dispose M	No	No	18	47,165	848.97 k	0
7 Nov 24	Sato Vicki L	Common Stock	Sell	Dispose S	No	Yes	30	1,020	30.60 k	111,056
7 Nov 24	Schuth Alexander O.	Common Stock	Sell	Dispose S	No	Yes	31.29	300	9.39 k	178,066

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Stifel Upgrades Denali Therapeutics to Buy, Announces $37 Price Target

16 Dec 24

Stifel analyst Paul Mattels upgrades Denali Therapeutics (NASDAQ:DNLI) from Hold to Buy and announces $37 price target.

HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $90 Price Target

7 Nov 24

HC Wainwright & Co. analyst Andrew Fein reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $90 price target.

Jefferies Maintains Buy on Denali Therapeutics, Raises Price Target to $45

1 Nov 24

Jefferies analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $40 to $45.

JP Morgan Maintains Overweight on Denali Therapeutics, Lowers Price Target to $28

11 Oct 24

Denali Therapeutics Stock Is Sliding After The Bell: Here's Why

10 Oct 24